Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2009

View Archived Issues

Novel GABA(A) modulator shows antinociceptive activity in vivo

Biodel to submit NDA for VIAject to FDA for diabetes

Studies with SAR-150640 show potential importance of ADRB3 agonists in preventing preterm labor

Studies determine optimal doses of sublingual immunotherapy with rBet v 1

Combination of paclitaxel and cyclophosphamide is safe in patients with bladder cancer

DSMB recommends continuation of Anthera's phase II IMPACTS clinical trial of A-001

Teva to use Compugen biomarkers for detection of drug-induced kidney toxicity

AVEO and Biogen sign definitive agreement for ErbB3-targeted antibodies

Gilead initiates phase II cicletanine trial for pulmonary arterial hypertension

FDA approves new indication for Wyeth's Tygacil

Novel orally bioavailable alkyl amines display in vivo renin inhibitory activity

Fablyn approved in Europe for the treatment of osteoporosis

Clinical study shows potential of kisspeptin-54 as a treatment for infertility

CV Therapeutics develops candidate SCD inhibitor for obesity, metabolic syndrome and diabetes

Novel IGF-1R inhibitor BMS-754807 in phase I development

CFFT grants Alnara exclusive worldwide rights to PERT therapy liprotamase

Nerviano Medical Sciences claims substituted indazole derivatives as kinase inhibitors

Oncolytics completes patient enrollment in REO 009 clinical trial of Reolysin and Gemzar

Novel pyrazoloquinoline and pyrazolonaphthyridine derivatives claimed by Novartis

HGS and Morphotek sign collaboration agreement for therapeutic monoclonal antibodies

Novartis claims novel parathyroid calcium-sensing receptor antagonists

NovaBay and Galderma sign global agreement to develop and commercialize Aganocide

Abilify oral solution 0.1% to be launched in Japan in April

Novel alpha-alkyl substituted N-acyltryptophanols discovered by Bayer Schering Pharma

Additional indication for Actos approved in Japan

Eisai claims novel polycyclic compounds against beta-amyloid load

Vertex commences phase II development for VX-809 in cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...